Hedge funds made big changes at drug companies in second quarter: filings

August 15, 2016 4:31 PM EDT

The Pfizer logo is seen at their world headquarters in Manhattan, New York, U.S., August 1, 2016. REUTERS/Andrew Kelly

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

By Svea Herbst-Bayliss

BOSTON (Reuters) - For many prominent hedge fund managers who bet Pfizer Inc and Allergan Plc would merge to become the world's biggest pharmaceuticals company, the second quarter started with a thud that sent many in search of new opportunities.

John Griffin's Blue Ridge Capital, Andreas Halvorsen's Viking Global Investors each slashed their firm's stakes in Allergan by more than half after news broke that Pfizer was walking away from the deal, according to so-called 13F regulatory filings released on Monday. Senator Investment Group and Jana Partners yanked their money from Pfizer.

The filings, which show U.S. stocks owned by investment managers at the end of the past quarter, are backward looking but they do identify by name the managers who moved after fresh regulation scuttled the $160 billion Pfizer-Allergan deal.

As investors mulled alternatives, even embattled drug maker Valeant Pharmaceutical International Inc's name emerged as a possible winner amid the wreckage.

Mutual fund giant Fidelity Investments, for example, bought 10 million Valeant shares to own 15.5 million at the end of the quarter. North Tide Capital put on a new position of 2.5 million shares, while Hexavest Inc raised its stake by more than ten-fold to 1.8 million shares.

Allergan's stock price dropped 14 percent, suggesting fund managers such as Eric Mindich's Eton Park, which sold all of its 1.8 million shares, made the right call. Viking Global cut its holdings by 60 percent to 1.93 million shares and Blue Ridge cut its stake by 53 percent to 700,000 shares. Sachem Head Capital Management reduced its position by 57 percent.

Not all big investors ran. Daniel Loeb's Third Point kept its Allergan investment largely intact at 4.9 million shares, while Seth Klarman's Baupost Group raised it by 16 percent to 2 million. Carl Icahn took a new position in Allergan, buying 3.4 million shares.

At Pfizer, which has been seeking a way to compete better with rivals that pay lower tax rates, Jana Partners sold 13 million shares and Senator sold 15 million shares. Jason Karp's Tourbillon exited its position and sold 7 million shares. But the exits may have been premature since the stock rose 16 percent, benefiting managers such as Diamond Hill, which increased its stake modestly to 11.6 million.

Tourbillon also exited all of its 3.4 million shares of Valeant, joining long-time holders Brave Warrior and Hound Partners, which had finally had enough. Even though Valeant brought in a new chief executive and a big investor continued to support the stock, it dropped 23 percent during the second quarter. Hound sold 4.9 million shares, while Brave Warrior exited 2 million shares.

There were some bright spots on the broader pharmaceutical sector, with a number of managers placing new bets on St. Jude Medical Inc, a manufacturer and distributor of medical devices whose stock surged 42 percent during the quarter. Farallon Capital made a new bet with 4.6 million shares, while Carlson Capital put on a wager with 2.05 million shares. Adage Capital boosted its holding by 227 percent to just under 1 million shares.

(Reporting by Svea Herbst-Bayliss; Editing by Steve Orlofsky)

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories


Related Entities

Daniel Loeb, Carl Icahn, JANA Partners LLC, Barry Rosenstein, Baupost Group, Seth Klarman, Third Point LLC, Farallon Capital Management, Blue Ridge Capital, Adage Capital Management, Viking Global Investors, Hedge Funds, Fidelity Investments, Eton Park Capital Management, Sachem Head Capital

Add Your Comment